Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | BPTF | Q12830 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19565802 | 0.77 | ALDH1A1 (0.41) | KMT2ASMN1; SMN2KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL1775854 | 0.71 | SMN1; SMN2 (0.56) | KMT2ASMN1; SMN2RAB9AKDM4EALDH1A1 | |
| SCHEMBL19564464 | 0.71 | KDM4E (0.37) | KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL13233395 | 0.69 | ALDH1A1 (0.46) | CYP1A2KMT2ABPTFSMN1; SMN2RAB9A | |
| SCHEMBL111337 | 0.69 | — | — | |
| SCHEMBL1455672 | 0.68 | HTR3E (0.50) | CYP1A2KMT2ASMN1; SMN2RAB9AKDM4E | |
| SCHEMBL24240194 | 0.67 | SMN1; SMN2 (0.44) | CYP1A2KMT2ABPTFSMN1; SMN2RAB9A | |
| SCHEMBL11453007 | 0.67 | SMN1; SMN2 (0.48) | CYP1A2KMT2ABPTFSMN1; SMN2RAB9A | |
| SCHEMBL11179382 | 0.67 | ALDH1A1 (0.51) | CYP1A2KMT2ABPTFSMN1; SMN2RAB9A | |
| SCHEMBL22855179 | 0.67 | TDP1 (0.39) | KMT2ASMN1; SMN2KDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8440672-B2 | Diphenyl substituted alkanes | MERCK SHARP & DOHME CORP. (US) | 2013-05-14 | — | — | US | disclosed |
| US-8440672-B2 | Diphenyl substituted alkanes | MERCK SHARP & DOHME CORP. (US) | 2013-05-14 | — | — | US | disclosed |
| US-8440672-B2 | Diphenyl substituted alkanes | MERCK SHARP & DOHME CORP. (US) | 2013-05-14 | — | — | US | disclosed |
| EP-2013174-B1 | DIARYL SUBSTITUTED ALKANES | MERCK SHARP & DOHME (US) | 2013-05-08 | — | — | EP | disclosed |
| EP-2013174-B1 | DIARYL SUBSTITUTED ALKANES | MERCK SHARP & DOHME (US) | 2013-05-08 | — | — | EP | disclosed |
| US-8426413-B2 | Diaryl substituted alkanes | MERCK SHARP & DOHME CORP. (US) | 2013-04-23 | — | — | US | disclosed |
| US-8426413-B2 | Diaryl substituted alkanes | MERCK SHARP & DOHME CORP. (US) | 2013-04-23 | — | — | US | disclosed |
| US-8426413-B2 | Diaryl substituted alkanes | MERCK SHARP & DOHME CORP. (US) | 2013-04-23 | — | — | US | disclosed |
| EP-2546232-A1 | Diphenyl Substituted Alkanes | Merck Sharp & Dohme Corp. (US) | 2013-01-16 | — | — | EP | disclosed |
| EP-2546232-A1 | Diphenyl Substituted Alkanes | Merck Sharp & Dohme Corp. (US) | 2013-01-16 | — | — | EP | disclosed |
| US-20090258851-A1 | DIARYL SUBSTITUTED ALKANES | MERCK SHARP & DOHME CORP. | 2009-10-15 | — | — | US | disclosed |
| US-20090258851-A1 | DIARYL SUBSTITUTED ALKANES | MERCK SHARP & DOHME CORP. | 2009-10-15 | — | — | US | disclosed |
| US-20090258851-A1 | DIARYL SUBSTITUTED ALKANES | MERCK SHARP & DOHME CORP. | 2009-10-15 | — | — | US | disclosed |
| CN-101466677-A | Diaryl substituted alkanes | MERCK & CO INC (US) | 2009-06-24 | — | — | CN | disclosed |
| EP-2064204-A1 | INHIBITORS OF 5 -LIPOXYGENASE ACTIVATING PROTEIN ( FLAP) | Merck & Co., Inc. (US) | 2009-06-03 | — | — | EP | disclosed |
| WO-2009048547-A1 | DIPHENYL SUBSTITUTED CYCLOALKANES | MERCK & CO., INC. (US) | 2009-04-16 | — | — | WO | disclosed |
| WO-2008156721-A1 | DIPHENYL SUBSTITUTED ALKANES | MERCK & CO., INC. (US) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008030369-A1 | INHIBITORS OF 5 -LIPOXYGENASE ACTIVATING PROTEIN ( FLAP) | MERCK & CO., INC. (US) | 2008-03-13 | — | — | WO | disclosed |
| WO-2008030369-A1 | INHIBITORS OF 5 -LIPOXYGENASE ACTIVATING PROTEIN ( FLAP) | MERCK & CO., INC. (US) | 2008-03-13 | — | — | WO | disclosed |
| WO-2007120574-A2 | DIARYL SUBSTITUTED ALKANES | MERCK & CO., INC. (US) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258851-A1 | DIARYL SUBSTITUTED ALKANES | ALOX5, ALOX15, LTB4R2 | CYP1A2 301/4885KMT2A 3411/4885BPTF 1671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.